Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

Documenti analoghi

• Regression of Established Human Papillomavirus Type 16 (HPV-16) Immortalized Tumors In Vivo by Vaccinia Viruses Expressing Different Forms of HPV-16 E7 Correlates with Enhanced CD8(+) T-Cell Responses That Home to the Tumor Site
  di: Lamikanra, Abigail, et al.
  Pubblicazione: (2001)
• Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer
  di: Souders, Nicholas C., et al.
  Pubblicazione: (2007)
• Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy
  di: Wood, Laurence M., et al.
  Pubblicazione: (2010)
• Listeria monocytogenes Delivery of HPV-16 Major Capsid Protein L1 Induces Systemic and Mucosal Cell-Mediated CD4(+) and CD8(+) T-Cell Responses After Oral Immunization
  di: Mustafa, Waleed, et al.
  Pubblicazione: (2009)
• Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
  di: Wood, Laurence M., et al.
  Pubblicazione: (2011)